To discuss the recent and emerging data for novel targeted therapies in myelodysplastic syndromes (MDS).
Data Sources:
A literature search from January 2015 to June 2021 was performed using the key terms targeted therapies, myelodysplastic syndromes, DNA repair, erythroid differentiation therapy, epigenetic inhibitors, signal transduction inhibitors, and apoptosis-inducing agents.
Study Selection and Data Extraction:
Relevant clinical trials and articles in the English language were identified and reviewed.
Data Synthesis:
MDS are a heterogeneous group of malignant blood disorders affecting the bone marrow (BM), ultimately leading to BM failure, acute leukemia, and death. Selection of treatment is influenced by the severity of symptoms, cytopenia, cytogenetics, prognostic category, medical fitness, and patient preferences. Although current therapies such as erythropoiesis stimulating agents (ESAs) and hypomethylating agents (HMAs) help improve anemia and reduce transfusion burden, limited treatment options exist when patients experience treatment failure to ESAs or HMA. Recent regulatory approval of luspatercept, which targets the erythroid differentiation pathway, represents a major therapeutic advance in the management of anemia in MDS patients who are refractory to ESAs. Many investigational targeted therapies that aim at the myeloid lineage signaling pathway and the immune microenvironment are in active development.
Relevance to Patient Care and Clinical Practice:
This nonexhaustive review summarizes and describes the recent data for targeted therapies for MDS.
Conclusion:
The development of novel and investigational therapeutic agents continues to contribute to an improved understanding of tumor biology. The precise therapeutic role and timing of these agents remain to be elucidated.
FrankeGNLückemeierPPlatzbeckerU.Allogeneic stem-cell transplantation in patients with myelodysplastic syndromes and prevention of relapse. Clin Lymphoma Myeloma Leuk. 2021;21:1-7. doi:10.1016/j.clml.2020.10.008
5.
GreenbergPCoxCLeBeauMM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
SteensmaDP.Historical perspectives on myelodysplastic syndromes. Leuk Res. 2012;36:1441-1452. doi:10.1016/j.leukres.2012.08.007
8.
CarrawayHESayginC.Therapy for lower-risk MDS. Hematology Am Soc Hematol Educ Program. 2020;2020:426-433. doi:10.1182/hematology.2020000127
9.
SantiniV.Treatment of low-risk myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2016;2016:462-469. doi:10.1182/asheducation-2016.1.462
10.
GreenbergPLTuechlerHSchanzJ, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454-2465. doi:10.1182/blood-2012-03-420489
11.
GermingUKündgenA.Prognostic scoring systems in MDS. Leuk Res. 2012;36:1463-1469. doi:10.1016/j.leukres.2012.08.005
12.
de WitteTBowenDRobinM, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129:1753-1762. doi:10.1182/blood-2016-06-724500
13.
FenauxPMuftiGJHellstrom-LindbergE, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223-232. doi:10.1016/S1470-2045(09)70003-8
14.
MalcovatiLHellström-LindbergEBowenD, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943-2964.
15.
BejarRLordAStevensonK, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124:2705-2712. doi:10.1182/blood-2014-06-582809
16.
WalterMJShenDShaoJ, et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia. 2013;27:1275-1282. doi:10.1038/leu.2013.58
17.
BusqueLPatelJPFigueroaME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44:1179-1181. doi:10.1038/ng.2413
18.
SteensmaDPBejarRJaiswalS, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9-16. doi:10.1182/blood-2015-03-631747
19.
BoultwoodJPellagattiANikpourM, et al. The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One. 2008;3:e1970. doi:10.1371/journal.pone.0001970
20.
SayginCCarrawayHE.Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021;48:100791. doi:10.1016/j.blre.2020.100791
21.
ListADewaldGBennettJ, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456-1465. doi:10.1056/NEJMoa061292
GuptaVBrookerCToozeJA, et al. Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults. Br J Haematol. 2006;134:95-99. doi:10.1111/j.1365-2141.2006.06105.x
24.
JacobsKBYeagerMZhouW, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet. 2012;44:651-658. doi:10.1038/ng.2270
25.
KordastiSYAfzaliBLimZ, et al. IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol. 2009;145:64-72. doi:10.1111/j.1365-2141.2009.07593.x
26.
SharmaBAltmanJKGoussetisDJ, et al. Protein kinase R as mediator of the effects of interferon (IFN) gamma and tumor necrosis factor (TNF) alpha on normal and dysplastic hematopoiesis. J Biol Chem. 2011;286:27506-27514. doi:10.1074/jbc.M111.238501
27.
BejarRStevensonKAbdel-WahabO, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496-2506. doi:10.1056/NEJMoa1013343
28.
RazaAReevesJAFeldmanEJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111:86-93. doi:10.1182/blood-2007-01-068833
29.
MayerIAArteagaCL.The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med. 2016;67:11-28. doi:10.1146/annurev-med-062913-051343
30.
BarrFASilljéHHNiggEA.Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol. 2004;5:429-440. doi:10.1038/nrm1401
31.
RennerAGDos SantosCRecherC, et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood. 2009;114:659-662. doi:10.1182/blood-2008-12-195867
32.
FanAXuLSridharK, et al. A novel nano-immunoassay (NIA) reveals inhibition of PI3K and MAPK pathways in CD34+ bone marrow cells of patients with myelodysplastic syndrome (MDS) treated with the multi-kinase inhibitor On 01910.Na (rigosertib). Blood. 2011;118:3808. doi:10.1182/blood.V118.21.3808.3808
33.
Athuluri-DivakarSKVasquez-Del CarpioRDuttaK, et al. A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling. Cell. 2016;165:643-655. doi:10.1016/j.cell.2016.03.045
NavadaSCGarcia-ManeroGAtallahEL, et al. Phase 2 expansion study of oral rigosertib combined with azacitidine (AZA) in patients (Pts) with higher-risk (HR) myelodysplastic syndromes (MDS): efficacy and safety results in HMA treatment naïve & relapsed (rel)/refractory (ref) patients. Blood. 2018;132:230. doi:10.1182/blood-2018-99-119259
36.
Garcia-ManeroGFenauxPAl-KaliA, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:496-508. doi:10.1016/S1470-2045(16)00009-7
37.
DillVKauschingerJHauchRT, et al. Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis. Eur J Haematol. 2020;104:125-137. doi:10.1111/ejh.13354
38.
PlatzbeckerUHofbauerLCEhningerG, et al. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk Res. 2012;36:525-536. doi:10.1016/j.leukres.2012.01.006
39.
HattangadiSMWongPZhangL, et al. From stem cell to red cell: regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications. Blood. 2011;118:6258-6268. doi:10.1182/blood-2011-07-356006
40.
BlankUKarlssonS.TGF-beta signaling in the control of hematopoietic stem cells. Blood. 2015;125:3542-3550. doi:10.1182/blood-2014-12-618090
41.
FujiwaraT.GATA transcription factors: basic principles and related human disorders. Tohoku J Exp Med. 2017;242:83-91. doi:10.1620/tjem.242.83
42.
MassagueJ.TGF-beta signal transduction. Annu Rev Biochem. 1998;67:753-791. doi:10.1146/annurev.biochem.67.1.753
43.
BlankUKarlssonS.The role of Smad signaling in hematopoiesis and translational hematology. Leukemia. 2011;25:1379-1388. doi:10.1038/leu.2011.95
44.
HeWDornDCErdjument-BromageHTempstPMooreMASMassaguéJ.Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell. 2006;125:929-941. doi:10.1016/j.cell.2006.03.045
SuraganiRNCadenaSMCawleySM, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20:408-414. doi:10.1038/nm.3512
47.
PlatzbeckerUGermingUGötzeKS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017;18:1338-1347. doi:10.1016/S1470-2045(17)30615-0
48.
FenauxPPlatzbeckerUMuftiGJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382:140-151. doi:10.1056/NEJMoa1908892
PortaMDPlatzbeckerUSantiniV, et al. The Commands trial: a phase 3 study of the efficacy and safety of luspatercept versus epoetin alfa for the treatment of anemia due to IPSS-R very low-, low-, or intermediate-risk MDS in erythropoiesis stimulating agent-naive patients who require RBC transfusions. Blood. 2020;136(suppl 1):1-2. doi:10.1182/blood-2020-140284
51.
CoreySJMindenMDBarberDL, et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer. 2007;7:118-129. doi:10.1038/nrc2047
52.
GreenbergPL.Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res. 1998;22:1123-1136. doi:10.1016/s0145-2126(98)00112-x
53.
WestwoodNBMuftiGJ.Apoptosis in the myelodysplastic syndromes. Curr Hematol Rep. 2003;2:186-192.
54.
ParkerJEMuftiGJRasoolF, et al. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood. 2000;96:3932-3938.
55.
JilgSReidelVMuller-ThomasC, et al. Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients. Leukemia. 2016;30:112-123. doi:10.1038/leu.2015.179
56.
SharmaPPollyeaDA.Shutting down acute myeloid leukemia and myelodysplastic syndrome with BCL-2 family protein inhibition. Curr Hematol Malig Rep. 2018;13:256-264. doi:10.1007/s11899-018-0464-8
57.
DiNardoCDPratzKPullarkatV, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7-17. doi:10.1182/blood-2018-08-868752
58.
WeiAHGarciaJSBorateU, et al. A phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacitidine in treatment-naïve patients with higher-risk myelodysplastic syndrome. Blood. 2019;134(suppl 1):568. doi:10.1182/blood-2019-124437
59.
ChungC.Restoring the switch for cancer cell death: targeting the apoptosis signaling pathway. Am J Health Syst Pharm. 2018;75:945-952. doi:10.2146/ajhp170607
60.
LindsleyRCSaberWMarBG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376:536-547. doi:10.1056/NEJMoa1611604
61.
JiangLZawacka-PankauJ.The p53/MDM2/MDMX-targeted therapies—a clinical synopsis. Cell Death Dis. 2020;11:237. doi:10.1038/s41419-020-2445-9
62.
SallmanDABorateUCullEH, et al. Phase 1/1b study of the stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, as monotherapy or in combination with cytarabine for the treatment of relapsed/refractory AML and advanced MDS with TP53 wild-type. Blood. 2018;132(suppl 1):4066. doi:10.1182/blood-2018-99-118780
63.
MullardA.p53 Programmes plough on. Nat Rev Drug Discov. 2020;19:497-500. doi:10.1038/d41573-020-00130-z
64.
SallmanDADeZernAEGarcia-ManeroG, et al. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol. 2021;39:1584-1594. doi:10.1200/JCO.20.02341
FenauxPMorelPLaiJL.Cytogenetics of myelodysplastic syndromes. Semin Hematol. 1996;33:127-138.
67.
ChangHPannunzioNAdachiN, et al. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol. 2017;18:495-506. doi:10.1038/nrm.2017.48
68.
GojoIBeumerJHPratzKW, et al. A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. Clin Cancer Res. 2017;23:697-706. doi:10.1158/1078-0432.CCR-16-0984
69.
DiNardoCDJabbourERavandiF, et al. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia. 2016;30:980-984. doi:10.1038/leu.2015.211
70.
ReitmanZJYanH.Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010;102:932-941. doi:10.1093/jnci/djq187
71.
ForanJMDiNardoCDWattsJM, et al. Ivosidenib (AG-120) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome: updated enrollment of a phase 1 dose escalation and expansion study. Blood. 2019;134(suppl 1):4254. doi:10.1182/blood-2019-123946
72.
SteinEMFathiATDiNardoCD, et al. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020;7:e309-e319. doi:10.1016/S2352-3026(19)30284-4
73.
StoddartAFernaldAAWangJ, et al. Haploinsufficiency of del (5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice. Blood. 2014;123:1069-1078. doi:10.1182/blood-2013-07-517953
74.
PrebetTZeidanA.Trends in clinical investigation for myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2016;16(suppl):S57-S63. doi:10.1016/j.clml.2016.02.012
75.
NazhaA.Does mutational burden add to other prognostic factors in MDS?Best Pract Res Clin Haematol. 2019;32:101098. doi:10.1016/j.beha.2019.101098
76.
YangHBueso-RamosCDiNardoC, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28:1280-1288. doi:10.1038/leu.2013.355
77.
ØrskovADTreppendahlMBSkovboA, et al. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: a rationale for combined targeting of PD-1 and DNA methylation. Oncotarget. 2015;6:9612-9626. doi:10.18632/oncotarget.3324
78.
MoritaKKantarjianHMBravoGM, et al. A phase II study of double immune checkpoint inhibitor blockade with nivolumab and ipilimumab with or without azacitidine in patients with myelodysplastic syndrome (MDS). Blood. 2020;136(suppl 1):7-9. doi:10.1182/blood-2020-142003
79.
GerdsATScottBLGreenbergPL, et al. PD-L1 blockade with atezolizumab in higher-risk myelodysplastic syndrome: an initial safety and efficacy analysis. Blood. 2018;132(suppl 1):466. doi:10.1182/blood-2018-99-118577
80.
MantovaniALongoDL.Macrophage checkpoint blockade in cancer: back to the future. N Engl J Med. 2018;379:1777-1779. doi:10.1056/NEJMe1811699
81.
CaseySCTongLLiY, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352:227-231. doi:10.1126/science.aaf7984
82.
SallmanDAAl MalkiMAschA, et al. The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in MDS patients: phase 1b results. Paper presented at: EHA Annual Meeting; November 19-21, 2020; virtual; S187.
83.
WarlickEDMillerJS.Myelodysplastic syndromes: the role of the immune system in pathogenesis. Leuk Lymphoma. 2011;52:2045-2049. doi:10.3109/10428194.2011.584002
84.
WeiYChenRDimicoliS, et al. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. Leukemia. 2013;27:2177-2186. doi:10.1038/leu.2013.91
85.
KiladjianJJBourgeoisELobeI, et al. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia. 2006;20:463-470. doi:10.1038/sj.leu.2404080
86.
FengYLiXCassadyKZouZZhangX.TET2 function in hematopoietic malignancies, immune regulation, and DNA repair. Front Oncol. 2019;9:210. doi:10.3389/fonc.2019.00210
87.
SaftLKarimiMGhaderiM, et al. p53 Protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica. 2014;99:1041-1049. doi:10.3324/haematol.2013.098103
88.
CaceresGMcGrawKYipBH, et al. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proc Natl Acad Sci U S A. 2013;110:16127-16132. doi:10.1073/pnas.1311055110
89.
HongSKerrCMRybickiL, et al. Pattern of somatic mutation changes from diagnosis to relapse following allogeneic hematopoietic cell transplantation (alloHCT) for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Blood. 2019;134(suppl 1):2716. doi:10.1182/blood-2019-130352
90.
MantovaniAMarchesiFMalesciALaghiLAllavenaP.Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399-416. doi:10.1038/nrclinonc.2016.217
91.
BewersdorfJPZeidanAM.Risk-adapted, individualized treatment strategies of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Cancers (Basel). 2021;13:1610. doi:10.3390/cancers13071610
